Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 0.80 |
| ▸ | FAP | Q12884 | 5/20 | 0.63 |
| ▸ | POU2F2 | P09086 | 1/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.63 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.63 |
| ▸ | POU2F1 | P14859 | 1/20 | 0.63 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.63 |
| ▸ | HRH2 | P25021 | 1/20 | 0.63 |
| ▸ | MC4R | P32245 | 1/20 | 0.63 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.63 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.63 |
| ▸ | GHSR | Q92847 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL639988 | 0.94 | DPP4 (0.83) | DPP4FAPPOU2F2ADORA3CHRM1 | |
| SCHEMBL637493 | 0.94 | DPP4 (0.83) | DPP4FAPPOU2F2ADORA3CHRM1 | |
| SCHEMBL14935777 | 0.94 | DPP4 (0.83) | DPP4FAPPOU2F2ADORA3CHRM1 | |
| SCHEMBL29576288 | 0.94 | DPP4 (0.83) | DPP4FAPPOU2F2ADORA3CHRM1 | |
| SCHEMBL638362 | 0.92 | DPP4 (0.83) | DPP4FAPPOU2F2ADORA3CHRM1 | |
| SCHEMBL637386 | 0.92 | DPP4 (0.81) | DPP4FAPPOU2F2ADORA3CHRM1 | |
| SCHEMBL637743 | 0.91 | DPP4 (0.81) | DPP4FAPPOU2F2ADORA3CHRM1 | |
| SCHEMBL3972211 | 0.91 | DPP4 (0.80) | DPP4FAPPOU2F2ADORA3CHRM1 | |
| SCHEMBL638911 | 0.91 | DPP4 (0.81) | DPP4FAPPOU2F2ADORA3CHRM1 | |
| SCHEMBL637857 | 0.91 | DPP4 (0.82) | DPP4FAPPOU2F2ADORA3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8697868-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-04-15 | — | — | US | disclosed |
| CN-1980930-B | 8- [ 3-amino-piperidin-1-yl ] -xanthines, their preparation and their use in the form of DPP-IV inhibitors | BOEHRINGER INGELHEIM INT | 2012-11-21 | — | — | CN | disclosed |
| US-20090137801-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | US | disclosed |
| US-7501426-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-10 | — | — | US | disclosed |
| US-20050234108-A1 | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137801-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP8, DPP4, DPP7 | DPP4 2/4885FAP 19/4885POU2F2 2574/4885 |
| US-20050234108-A1 | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions | DPP8, DPP4, DPP7 | DPP4 2/4885FAP 21/4885POU2F2 2452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.